IL273253B2 - Glucagon-like peptide-1 receptor agonists and their uses - Google Patents

Glucagon-like peptide-1 receptor agonists and their uses

Info

Publication number
IL273253B2
IL273253B2 IL273253A IL27325320A IL273253B2 IL 273253 B2 IL273253 B2 IL 273253B2 IL 273253 A IL273253 A IL 273253A IL 27325320 A IL27325320 A IL 27325320A IL 273253 B2 IL273253 B2 IL 273253B2
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
antigen
disease
fusion protein
binding fragment
Prior art date
Application number
IL273253A
Other languages
English (en)
Hebrew (he)
Other versions
IL273253B1 (en
IL273253A (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL273253A publication Critical patent/IL273253A/en
Publication of IL273253B1 publication Critical patent/IL273253B1/en
Publication of IL273253B2 publication Critical patent/IL273253B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
IL273253A 2017-09-22 2018-09-21 Glucagon-like peptide-1 receptor agonists and their uses IL273253B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762562283P 2017-09-22 2017-09-22
PCT/US2018/052110 WO2019060653A1 (en) 2017-09-22 2018-09-21 GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF

Publications (3)

Publication Number Publication Date
IL273253A IL273253A (en) 2020-04-30
IL273253B1 IL273253B1 (en) 2024-03-01
IL273253B2 true IL273253B2 (en) 2024-07-01

Family

ID=63799082

Family Applications (2)

Application Number Title Priority Date Filing Date
IL273253A IL273253B2 (en) 2017-09-22 2018-09-21 Glucagon-like peptide-1 receptor agonists and their uses
IL304574A IL304574B2 (en) 2017-09-22 2018-09-21 Glucagon-like peptide 1 receptor agonists and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL304574A IL304574B2 (en) 2017-09-22 2018-09-21 Glucagon-like peptide 1 receptor agonists and uses thereof

Country Status (14)

Country Link
US (4) US11045522B2 (enExample)
EP (1) EP3684793A1 (enExample)
JP (3) JP7239566B2 (enExample)
KR (1) KR102696518B1 (enExample)
CN (2) CN118955732A (enExample)
AU (2) AU2018338178B2 (enExample)
CA (1) CA3073964A1 (enExample)
EA (1) EA202090649A1 (enExample)
IL (2) IL273253B2 (enExample)
MX (1) MX2020002977A (enExample)
MY (2) MY207828A (enExample)
SG (1) SG11202001637PA (enExample)
WO (1) WO2019060653A1 (enExample)
ZA (1) ZA202001167B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7239566B2 (ja) * 2017-09-22 2023-03-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
WO2022119076A1 (ko) * 2020-12-03 2022-06-09 이뮤노포지 주식회사 Glp-1 수용체 작용제 및 항-오스카 항체를 포함하는 융합 단백질 및 이의 용도
WO2022117044A1 (en) * 2020-12-03 2022-06-09 Sunshine Lake Pharma Co., Ltd. Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof
CN112716966B (zh) * 2021-02-03 2022-05-03 浙江诺得药业有限公司 一种恩格列净药用组合物及其制备方法
CN113461785B (zh) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 Glp-1受体激动剂及其应用
CN119638849A (zh) * 2021-10-18 2025-03-18 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
CN114788876B (zh) * 2022-02-24 2024-07-05 北京医院 治疗糖尿病的mRNA药物制剂及其制备方法与应用
US20250289861A1 (en) * 2022-05-04 2025-09-18 Immunoforge Co.,Ltd. Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250270274A1 (en) * 2024-02-26 2025-08-28 Serpentide Inc. Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101229610B1 (ko) * 2009-10-09 2013-02-05 한남대학교 산학협력단 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
TW200843794A (en) 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
US20110034373A1 (en) 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
DK2373681T3 (en) 2008-12-10 2017-04-24 Glaxosmithkline Llc PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011056644A2 (en) 2009-10-28 2011-05-12 Centocor Ortho Biotech Inc. Anti-glp-1r antibodies and their uses
WO2011056713A2 (en) 2009-11-03 2011-05-12 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for obstructive sleep apnea
CA2880929A1 (en) 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
WO2014113357A1 (en) 2013-01-17 2014-07-24 Transtech Pharma, Llc Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
US20150259416A1 (en) 2014-03-12 2015-09-17 Biocrine Ab Methods for treating and/or limiting development of diabetes
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
CN104098702B (zh) * 2014-07-23 2017-06-16 湖北工业大学 一种利用mfh融合蛋白制备glp‑1多肽或其类似物方法和应用
CN104645317B (zh) * 2015-01-28 2020-04-17 中国科学院天津工业生物技术研究所 一种多肽复合物作为多肽或蛋白质药物载体的应用、方法及其融合蛋白复合物
ES2833099T3 (es) 2015-02-11 2021-06-14 Gmax Biopharm Llc Preparación de disolución estabilizada de una proteína de fusión de un anticuerpo de GLP-1R farmacéutica
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
AU2017277594A1 (en) * 2016-06-09 2019-02-07 Medimmune Limited Protease-resistant mono-lipidated peptides
JP7239566B2 (ja) * 2017-09-22 2023-03-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101229610B1 (ko) * 2009-10-09 2013-02-05 한남대학교 산학협력단 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HYE-SHIN CHUNG ET AL:, THE N-TERMINAL ALANINE-EXTENDED GLP-1/ IGG-FC FUSION PROTEIN CONFERS RESISTANCE TO DPP-IV AND REDUCES SERUM GLUCOSE LEVEL IN DB/DB MICE, 1 October 2011 (2011-10-01) *
ONG-MO KIM ET AL:, NOVEL AGLP-1 ALBUMIN FUSION PROTEIN AS A LONG- LASTING AGENT FOR TYPE 2 DIABETES, 31 December 2013 (2013-12-31) *

Also Published As

Publication number Publication date
EP3684793A1 (en) 2020-07-29
JP2023071827A (ja) 2023-05-23
AU2018338178A1 (en) 2020-04-02
SG11202001637PA (en) 2020-03-30
US20190091296A1 (en) 2019-03-28
EA202090649A1 (ru) 2020-06-29
MY207828A (en) 2025-03-21
US20250000949A1 (en) 2025-01-02
US20240024428A1 (en) 2024-01-25
KR102696518B1 (ko) 2024-08-21
AU2023223010B2 (en) 2025-12-04
CN118955732A (zh) 2024-11-15
WO2019060653A1 (en) 2019-03-28
KR20200054303A (ko) 2020-05-19
US20210283225A1 (en) 2021-09-16
US11045522B2 (en) 2021-06-29
IL273253B1 (en) 2024-03-01
US12090193B2 (en) 2024-09-17
US11779633B2 (en) 2023-10-10
JP7559112B2 (ja) 2024-10-01
CA3073964A1 (en) 2019-03-28
IL304574B1 (en) 2025-04-01
JP7239566B2 (ja) 2023-03-14
AU2018338178B2 (en) 2023-06-08
CN111108117B (zh) 2024-08-06
ZA202001167B (en) 2024-06-26
MY200364A (en) 2023-12-21
AU2023223010A1 (en) 2023-11-09
IL304574A (en) 2023-09-01
JP7789871B2 (ja) 2025-12-22
CN111108117A (zh) 2020-05-05
IL273253A (en) 2020-04-30
JP2020534016A (ja) 2020-11-26
MX2020002977A (es) 2020-11-06
JP2024178255A (ja) 2024-12-24
IL304574B2 (en) 2025-08-01

Similar Documents

Publication Publication Date Title
IL273253B1 (en) Glucagon-like peptide 1 receptor agonists and uses thereof
JP2023071827A5 (enExample)
JP7094327B2 (ja) 新規なオキシントモジュリン誘導体及びそれを含む肥満治療用組成物
Tahrani et al. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Rajeev et al. GLP-1 as a target for therapeutic intervention
CN120754229A (zh) 使用gip/glp1共激动剂用于治疗的方法
UA127445C2 (uk) Комбінація для лікування або профілактики метаболічного синдрому
AU2001263230A1 (en) Treatment of acute coronary syndrome with GLP-1
TW201305195A (zh) 包含調酸素與免疫球蛋白片段之複合物及其用途
TW201639878A (zh) 具有改善之安定性的升糖素衍生物
CN105263957A (zh) 治疗肽
CN109069589B (zh) 用于心血管病况的司美鲁肽
JP7191043B2 (ja) 慢性腎疾患の治療のためのデュラグルチド
JP2016528198A5 (enExample)
TWI696631B (zh) 升糖素衍生物
Boada et al. Current medical treatment of diabetes type 2 and long term morbidity: how to balance efficacy and safety?
JP2018518485A5 (enExample)
KR102022682B1 (ko) 당뇨병 치료용 조성물
Evans et al. Oral and injectable (non-insulin) pharmacological agents for type 2 diabetes
Aijazi et al. Exenatide induced acute kidney injury
Alghamdi et al. Bridging the gap between diabetes and cardiovascular disease: a comparative review of different glucagon-like peptide-1 (GLP-1) agonists: efficacy, safety, and patient outcomes
Maney et al. The cardiovascular benefits of new diabetes drugs
Salerno et al. GLP1-RAs: long-term use versus discontinuation events of an emerging therapy for obesity and cardiovascular diseases
Hussain Semaglutide Evolving Role: A Call for Broader Clinical Research in Pakistan
Krause Exenatide LAR: a sustained-release formulation of exenatide for the treatment of type 2 diabetes